生物制剂防治造血干细胞移植致口腔黏膜炎的研究进展  

Research Progress in Prevention and Treatment of Biological Agents for Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation

作　　者：郭锦材 张树生 GUO Jincai;ZHANG Shusheng(Department of Pharmacy,Changsha Stomatological Hospital,Changsha 410006,China;Changsha Stomatological Hospital,Changsha 410006,China;School of Stomatology,Hunan University of Chinese Medicine,Changsha 410006,China;School of Pharmacy,Hunan University of Chinese Medicine,Changsha 410208,China)

机构地区：[1]长沙市口腔医院药剂科,湖南长沙410006 [2]长沙市口腔医院,湖南长沙410006 [3]湖南中医药大学口腔医学院,湖南长沙410006 [4]湖南中医药大学药学院,湖南长沙410208

出　　处：《口腔医学研究》2023年第7期582-585,共4页Journal of Oral Science Research

基　　金：湖南省重点领域研发计划(编号:2020SK2137);湖南省自然科学基金(编号:2021JJ70062);长沙市自然科学基金(编号:kq2014019);湖南省医学会医学科研基金临床药学项目(编号:HMA202001012);湖南省保健委专项资金科研课题(编号:B2020-07)。

摘　　要：造血干细胞移植(hematopoietic stem cell transplantation,HSCT)是血液恶性肿瘤重要的治疗方式之一,但该治疗方法常致口腔黏膜炎(oral mucositis,OM)。造血干细胞移植致口腔黏膜炎(HSCT-OM)发生率高,临床治疗棘手。近几年有较多生物制剂探索性应用于HSCT-OM的治疗,部分生物制剂治疗效果较好。本文对防治HSCT-OM生物制剂的临床研究做一综述,为HSCT-OM的临床防治和研究提供参考。Hematopoietic stem cell transplantation(HSCT)is one of the most important treatment modalities for hematologic malignancies,but this treatment often causes oral mucositis(OM).The incidence of OM caused by HSCT(HSCT-OM)is high and the clinical treatment is difficult.Many biologic agents have been used exploratively in the treatment of HSCT-OM and some are effective.This paper reviews the clinical studies of biologic agents,and provides a reference for the clinical prevention and treatment of HSCT-OM.

关 键 词：造血干细胞移植 口腔黏膜炎 生物制剂 

分 类 号：R457.7[医药卫生—治疗学] R781.5[医药卫生—临床医学]